Key facts
- This page summarizes Melissa B. Epperly's Form 4 filing for Zentalis Pharmaceuticals, Inc. (ZNTL).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Oct 2023, 19:18.
Melissa B. Epperly - 04 Oct 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ZNTL
- Reported as of
- 04 Oct 2023
- Net transaction value
- -$106,926
- SEC form
- 4
- Accepted by SEC
- 06 Oct 2023, 19:18:52 UTC
- Prior SEC filing
- 14 Sep 2023
- Next SEC filing
- 18 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Melissa B. Epperly
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Melissa B. Epperly filed Form 4 for Zentalis Pharmaceuticals, Inc. (ZNTL) on 06 Oct 2023.
Change
- Previous filing in this sequence was filed on 14 Sep 2023.
- Current net transaction value: -$106,926.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZNTL
transaction
Common Stock
Sale
- Transaction value
- $89,245
- Shares
- -4,594
- Change %
- -1.2%
- Price
- $19.43
- Shares after
- 388,579
- Date
- 04 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
ZNTL
transaction
Common Stock
Sale
- Transaction value
- $17,680
- Shares
- -888
- Change %
- -0.23%
- Price
- $19.91
- Shares after
- 387,691
- Date
- 04 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
Footnote F2
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023.
Footnote F4
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.